The Indian pharmaceutical industry is famously known as the “pharmacy of the world.” It is expected to touch about $130 billion by 2030 and $450 billion by 2047. This forms part of the Indiasophia9100 vision. Contract manufacturing has been an important step in this journey, because companies can scale up and save costs, and this way, meet the ever-growing demands all over the globe. Read on to know how contract manufacturing is becoming the efficiency and innovation game-changer for the Indian pharmaceutical industry.
Contract Manufacturing’s Role in the Pharmaceutical Industry
Contract manufacturing is a scenario in the pharmaceutical sector whereby third-party specialized manufacturers manufacture drugs outsourced by pharmaceutical companies. The companies are free to concentrate on their core competencies such as R&D, marketing, and distribution. However, the complex processes of production are left in the hands of experts. This is a model that has picked up much speed in India, as there are many strategic advantages to contract manufacturing. This further receives a boost from the fact that there is an enormous network of top API manufacturers in India who supply active pharmaceutical ingredients required for the production.
Contract Manufacturing in India – The Present State
The Indian contract manufacturing market is enormous, with about 3,000 drug companies and more than 10,500 manufacturing units. About 500 API manufacturers contribute around 8% to the global API market, which underlines the strength of India’s API industry. Along with government initiatives such as 100 percent FDI route and the PLI scheme, this industry is quite capable of meeting worldwide demands which also enhances the capacity of top API manufacturers in India. Together, all these make the country an attractive investment destination and nudges towards self-reliance in key pharmaceuticals ingredients. All these go toward building an appropriate support structure for India’s contract manufacturing ecosystem.
Why Contract Manufacturing is Essential
Cost Efficiency
An in-house manufacturing facility requires enormous capital investment in infrastructure, technology, and regulatory compliance. Contracting out the process to contract manufacturers erases these costs because there is already an established pharmaceutical manufacturer company with capabilities in pharmaceutical production. It makes drug-making cheaper and allows even minor companies to have access to quality production facilities.
Faster Time-to-Market
In the cutthroat pharmaceutical industry, the only way for a pharmaceutical manufacturer company to maintain lead is to bring products to the market quickly. Contract manufacturing therefore offers a much faster way of production and allows to gain early market share which is very critical especially in the case of generics.
Emphasize R&D and Innovation
The production can be outsourced to pharmaceutical companies so that the resources available for R&D can be increased. Innovative drugs and biosimilars production keeps these companies competitive in pursuit of new drug discoveries. It also serves the wider objective of integrating India’s pharmaceutical sector into the world market.
Ready Availability of Advanced Technology and Knowledge
The contract manufacturers are defined by their investment in state-of-the-art technology and equipment. When one joins hands with them, they acquire those sophisticated capabilities which are usually very costly to build in-house. They maintain uncompromising standards of quality while keeping the most stringent regulations responsible for turning India into a reliable pharma production hub.
Challenges in the Contract Manufacturing Ecosystem
Despite its advantages, contract manufacturing in India faces challenges:
1. Complex Selection Process
In today’s drug market, contract manufacturing partnering is not so easy. It takes close to 12 months before a finalized contract is entered into by the parties concerned. If the drug is a complex formulation, even that timeframe is extended, adding on to the market time available for a generics segment that thrives more on timely-to-market positioning.
2. Quality and Compliance
Maintaining quality and regulatory compliance is very important because lack of compliance may delay approval of the product. High standards are ensured by the contract manufacturers following guidelines set by agencies such as the U.S. FDA and the European Medicines Agency.
3. Fragmented Market
India’s contract manufacturing market is highly fragmented with over 5,000 CMOs. Such a fragmented market can be very cumbersome while searching for the perfect partner who meets quality and compliance standards.
The Future of Contract Manufacturing in India’s Pharma Industry
Looking ahead, contract manufacturing will have a crucial role in the Indian pharmaceutical sector. As India continues to become a more significant hub of global pharmaceuticals, so opportunities for international collaborations are multiplying. Specialised manufacturing especially in biologics and personalized medicine is fast becoming of prime importance. Finally, technological advancement, such as automation and digital supply chain, is also changing the manufacturing process, and thus is making contract manufacturing more efficient and reliable.
There is an increasing push for environmental-friendly practices. Waste reduction and energy saving measures have become highly valued by contract manufacturers. These initiatives does not only abide by the international standards but also live up to the expectations of international clients who give top priority to green practices.
Conclusion
Contract manufacturing is, indeed the future enabler for growth in the Indian pharmaceutical industry. Here, companies have an opportunity strategically to reduce costs, improve time-to-market, and focus on innovation. Challenging decisions are also involved in selecting and managing contract partners, but the cumulative benefits are quite high. Contract manufacturing will form an important part of the attainment of India’s growth goals and reassertion as the “pharmacy of the world” as it cements its position further in the global pharmaceutical industry.
Leave a comment